Abstract 1845P
Background
ICIs are used in many solid tumors and is better tolerated than chemotherapy. However, irAEs are a concerning toxicity. Studies suggest that BMI may influence irAEs rates. We conducted a population-level study to evaluate BMI on irAEs and acute care use in patients receiving ICIs.
Methods
We used administrative data deterministically linked across databases to identify a cohort of solid tumors patients initiating ICI therapy in Ontario, Canada from June 2012-October 2018. We collected information on socio-demographics including BMI at start of ICI, clinical covariates and outcomes including acute care use and irAEs within 120 days of the last ICI dose. Multivariable Fine Gray competing risk analyses evaluated the impact of BMI on irAEs and acute care use, treating death as a competing event.
Results
Among 4683 patients, median age was 67, 57% were male; 46% had lung cancer, 35% melanoma, 9% renal; Median BMI was 26.1 (3% low, 29% normal, 27% overweight, 19% obese). Overall, 57% had an acute care episode while 7% of patients had an irAE requiring hospitalization. Increased BMI was associated with increased rate of irAEs (aHR=1.03 per 1 unit increase, 95% CI [1.01-1.04] p<0.001). Compared to patients with normal BMI, obese (aHR=1.60 [1.21-2.11] p<0.001) patients had a higher rate of irAEs. Subgroup analysis by gender found that females with increasing BMI (aHR=1.03 per unit increase [1.00-1.06] p=0.02) and obesity (aHR=2.01 [1.30-3.09] p=0.002) had higher rates of irAEs. Disease site analyses found that in patients with melanoma, obesity when compared to normal BMI (aHR=1.67 [1.10-2.53] p=0.02) was associated with increase in irAEs. In particular, in females with melanoma, obesity compared to normal BMI was strongly associated with increased irAEs (aHR=2.60 [1.36-4.96] p<0.004). BMI was not associated with overall general acute care use as a continuous or categorical variable (p>0.05).
Conclusions
Increasing BMI and obesity is associated with increasing risk for irAEs but not acute care use. The association was strongest for female patients and those with melanoma. Further research is needed to understand the mechanism of action behind this association.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Eng.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1832P - Physical condition is associated with quality of life in colorectal cancer survivors: Results from a Portuguese and Spanish cohort of patients
Presenter: Luisa Soares Miranda
Session: Poster session 12
1833P - JUMP_START: Optimization of multiprofessional care for young patients with colorectal cancer
Presenter: Kaiyu Xu
Session: Poster session 12
1834P - Accuracy of recommendations by a conversational Artificial Intelligence (AI) cancer mentor application (app): A multi-disciplinary, multi-institutional evaluation report
Presenter: Talia Golan
Session: Poster session 12
1835P - Multi-centre, randomised controlled trial of digital health cancer solution for cancer patients receiving chemotherapy
Presenter: Agnieszka Michael
Session: Poster session 12
1836P - Patient-reported health behaviors (PRHB) among 1850 patients enrolled in a remote patient monitoring (RPM) pathway
Presenter: Maria Alice Franzoi
Session: Poster session 12
1837P - Assessing care complexity in remote patient monitoring (RPM): A cohort study of 2434 cancer patients across 50 sites in France and Belgium
Presenter: Capucine Baldini
Session: Poster session 12
1838P - AI-based smart oncology follow-up system: Prospective application testing and enhancement of clinical efficacy
Presenter: Chunwei Xu
Session: Poster session 12
1839P - Dynamic reporting of treatment related symptoms via ePROs can reversely identify the type of underlying cancer
Presenter: Andreas Trojan
Session: Poster session 12
1840P - Ready for digital health? A national mirror survey exploring the perspectives of both patients and healthcare professionals
Presenter: Florian Scotté
Session: Poster session 12
1841P - Feasibility of wrist-worn health-tracker data to predict the need for therapy modifications in patients with metastatic cancer
Presenter: Anna Sophie Berghoff
Session: Poster session 12